Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20 μg/mL using a regimen of 12 mg/kg for five doses within the initial 3 days

BACKGROUND: A trough concentration (C(min)) ≥20 μg/mL of teicoplanin is recommended for the treatment of serious methicillin-resistant Staphylococcus aureus (MRSA) infections. However, sufficient clinical evidence to support the efficacy of this target C(min) has not been obtained. Even though the r...

Descripción completa

Detalles Bibliográficos
Autores principales: Ueda, Takashi, Takesue, Yoshio, Nakajima, Kazuhiko, Ichiki, Kaoru, Ishikawa, Kaori, Takai, Yoshiko, Yamada, Kumiko, Tsuchida, Toshie, Otani, Naruhito, Takahashi, Yoshiko, Ishihara, Mika, Takubo, Shingo, Ikeuchi, Hiroki, Uchino, Motoi, Kimura, Takeshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7341468/
https://www.ncbi.nlm.nih.gov/pubmed/32641110
http://dx.doi.org/10.1186/s40360-020-00424-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7341468/
https://www.ncbi.nlm.nih.gov/pubmed/32641110
http://dx.doi.org/10.1186/s40360-020-00424-3

Ejemplares similares